Characterization of Human c-fos and c-jun Gene Expression and Epignetic Regulation in TSA treated MCF7
碩士 === 國立陽明大學 === 生化暨分子生物研究所 === 97 === The study of gene expression based on epigenetic regulation level mainly includes DNA methylation and histone modifications. According to previous studies, the cell cycle of MCF-7 becomes arrested in G0/G1 phase and apoptosis is induced after TSA treatment for...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Language: | zh-TW |
Published: |
2009
|
Online Access: | http://ndltd.ncl.edu.tw/handle/6nv7t5 |
id |
ndltd-TW-097YM005107030 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-TW-097YM0051070302019-05-15T20:21:08Z http://ndltd.ncl.edu.tw/handle/6nv7t5 Characterization of Human c-fos and c-jun Gene Expression and Epignetic Regulation in TSA treated MCF7 從附基因調控層次上探討TSA處理後人類乳癌細胞MCF7中c-fos及c-jun基因表現差異之機制 Wen-Ting Hsieh 謝文定 碩士 國立陽明大學 生化暨分子生物研究所 97 The study of gene expression based on epigenetic regulation level mainly includes DNA methylation and histone modifications. According to previous studies, the cell cycle of MCF-7 becomes arrested in G0/G1 phase and apoptosis is induced after TSA treatment for 24 hours. C-fos and c-jun are immediate early genes that form the AP-1 complex. The AP-1 complex is a very important transcription factor that regulates many downstream genes including genes that regulate cell growth and apoptosis. Based on affymetrix microarray data, c-fos and c-jun were upregulated after 24 hours treatment of TSA in MCF-7. TSA is an anti-cancer drug and also a HDACi (histone deacetylase inhibitor) drug that alters epigenetic mechanism. I used bisulfite sequencing to study the DNA methylation pattern of the whole gene and the promoter region of c-fos and c-jun after TSA treatment. I also used ChIP to study the histone modifications of c-fos and c-jun. I found that the DNA methylation pattern of c-jun showed similar patterns before and after TSA treatment. However, the upstream 2000 bps and intron 1 of c-fos becomes unmethylated after TSA treatment. According to ChIP analysis, the level of H3K9 acetylation of c-fos and c-jun increases after TSA treatment. Finally, the results revealed that TSA may affect the demethylation of first intron of c-fos DNA, decrease H3K9 dimethylation and increase H3K9 acetylation to relieve the premature termination block site in intron 1 and upregulate c-fos expression. TSA treatment resulted in the decreased H3K9 dimethylation and increased H3K9 acetylation at the CpG island shore of c-jun to upregulate c-jun expression without affecting the DNA methylation of the gene. The epigenetic regulation mechanism of this gene therefore is at histone modification level but not at DNA methylation level. Ming-Ta Hsu 徐明達 2009 學位論文 ; thesis 66 zh-TW |
collection |
NDLTD |
language |
zh-TW |
format |
Others
|
sources |
NDLTD |
description |
碩士 === 國立陽明大學 === 生化暨分子生物研究所 === 97 === The study of gene expression based on epigenetic regulation level mainly includes DNA methylation and histone modifications. According to previous studies, the cell cycle of MCF-7 becomes arrested in G0/G1 phase and apoptosis is induced after TSA treatment for 24 hours. C-fos and c-jun are immediate early genes that form the AP-1 complex. The AP-1 complex is a very important transcription factor that regulates many downstream genes including genes that regulate cell growth and apoptosis. Based on affymetrix microarray data, c-fos and c-jun were upregulated after 24 hours treatment of TSA in MCF-7. TSA is an anti-cancer drug and also a HDACi (histone deacetylase inhibitor) drug that alters epigenetic mechanism. I used bisulfite sequencing to study the DNA methylation pattern of the whole gene and the promoter region of c-fos and c-jun after TSA treatment. I also used ChIP to study the histone modifications of c-fos and c-jun. I found that the DNA methylation pattern of c-jun showed similar patterns before and after TSA treatment. However, the upstream 2000 bps and intron 1 of c-fos becomes unmethylated after TSA treatment. According to ChIP analysis, the level of H3K9 acetylation of c-fos and c-jun increases after TSA treatment. Finally, the results revealed that TSA may affect the demethylation of first intron of c-fos DNA, decrease H3K9 dimethylation and increase H3K9 acetylation to relieve the premature termination block site in intron 1 and upregulate c-fos expression. TSA treatment resulted in the decreased H3K9 dimethylation and increased H3K9 acetylation at the CpG island shore of c-jun to upregulate c-jun expression without affecting the DNA methylation of the gene. The epigenetic regulation mechanism of this gene therefore is at histone modification level but not at DNA methylation level.
|
author2 |
Ming-Ta Hsu |
author_facet |
Ming-Ta Hsu Wen-Ting Hsieh 謝文定 |
author |
Wen-Ting Hsieh 謝文定 |
spellingShingle |
Wen-Ting Hsieh 謝文定 Characterization of Human c-fos and c-jun Gene Expression and Epignetic Regulation in TSA treated MCF7 |
author_sort |
Wen-Ting Hsieh |
title |
Characterization of Human c-fos and c-jun Gene Expression and Epignetic Regulation in TSA treated MCF7 |
title_short |
Characterization of Human c-fos and c-jun Gene Expression and Epignetic Regulation in TSA treated MCF7 |
title_full |
Characterization of Human c-fos and c-jun Gene Expression and Epignetic Regulation in TSA treated MCF7 |
title_fullStr |
Characterization of Human c-fos and c-jun Gene Expression and Epignetic Regulation in TSA treated MCF7 |
title_full_unstemmed |
Characterization of Human c-fos and c-jun Gene Expression and Epignetic Regulation in TSA treated MCF7 |
title_sort |
characterization of human c-fos and c-jun gene expression and epignetic regulation in tsa treated mcf7 |
publishDate |
2009 |
url |
http://ndltd.ncl.edu.tw/handle/6nv7t5 |
work_keys_str_mv |
AT wentinghsieh characterizationofhumancfosandcjungeneexpressionandepigneticregulationintsatreatedmcf7 AT xièwéndìng characterizationofhumancfosandcjungeneexpressionandepigneticregulationintsatreatedmcf7 AT wentinghsieh cóngfùjīyīndiàokòngcéngcìshàngtàntǎotsachùlǐhòurénlèirǔáixìbāomcf7zhōngcfosjícjunjīyīnbiǎoxiànchàyìzhījīzhì AT xièwéndìng cóngfùjīyīndiàokòngcéngcìshàngtàntǎotsachùlǐhòurénlèirǔáixìbāomcf7zhōngcfosjícjunjīyīnbiǎoxiànchàyìzhījīzhì |
_version_ |
1719097214259691520 |